161 related articles for article (PubMed ID: 10550142)
1. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
Ganjoo KN; Chan RJ; Sharma M; Einhorn LH
J Clin Oncol; 1999 Nov; 17(11):3457-60. PubMed ID: 10550142
[TBL] [Abstract][Full Text] [Related]
2. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma.
Warren GP; Einhorn LH
J Clin Oncol; 1995 Nov; 13(11):2784-8. PubMed ID: 7595739
[TBL] [Abstract][Full Text] [Related]
3. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
4. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
5. Postchemotherapy residual masses in advanced seminoma: current management and outcomes.
Quek ML; Simma-Chiang V; Stein JP; Pinski J; Quinn DI; Skinner DG
Expert Rev Anticancer Ther; 2005 Oct; 5(5):869-74. PubMed ID: 16221056
[TBL] [Abstract][Full Text] [Related]
6. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
7. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
8. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
9. [Management of advanced seminoma: retrospective study of 96 patients].
Bompas E; Fléchon A; Biron P; Droz JP
Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
[TBL] [Abstract][Full Text] [Related]
10. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
11. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
12. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer.
Onozawa M; Kawai K; Yamamoto T; Hinotsu S; Tsukamoto S; Hattori K; Miyanaga N; Shimazui T; Akaza H
Int J Urol; 2004 Jul; 11(7):535-41. PubMed ID: 15242364
[TBL] [Abstract][Full Text] [Related]
13. Management of post-chemotherapy residual masses in advanced seminoma.
Flechon A; Bompas E; Biron P; Droz JP
J Urol; 2002 Nov; 168(5):1975-9. PubMed ID: 12394688
[TBL] [Abstract][Full Text] [Related]
14. Management of stage II seminoma.
Warde P; Gospodarowicz M; Panzarella T; Catton C; Sturgeon J; Moore M; Jewett M
J Clin Oncol; 1998 Jan; 16(1):290-4. PubMed ID: 9440755
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma.
Miller KD; Loehrer PJ; Gonin R; Einhorn LH
J Clin Oncol; 1997 Apr; 15(4):1427-31. PubMed ID: 9193335
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
Fosså SD; Droz JP; Stoter G; Kaye SB; Vermeylen K; Sylvester R
Br J Cancer; 1995 Mar; 71(3):619-24. PubMed ID: 7880748
[TBL] [Abstract][Full Text] [Related]
17. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
18. Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report.
Iwasa S; Ando M; Ono M; Hirata T; Yunokawa M; Nakano E; Yonemori K; Kouno T; Shimizu C; Tamura K; Katsumata N; Fujiwara Y
Jpn J Clin Oncol; 2009 Jul; 39(7):456-9. PubMed ID: 19395465
[TBL] [Abstract][Full Text] [Related]
19. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
Puc HS; Heelan R; Mazumdar M; Herr H; Scheinfeld J; Vlamis V; Bajorin DF; Bosl GJ; Mencel P; Motzer RJ
J Clin Oncol; 1996 Feb; 14(2):454-60. PubMed ID: 8636757
[TBL] [Abstract][Full Text] [Related]
20. VAB-6 as initial treatment of patients with advanced seminoma.
Stanton GF; Bosl GJ; Whitmore WF; Herr H; Sogani P; Morse M; Golbey RB
J Clin Oncol; 1985 Mar; 3(3):336-9. PubMed ID: 2579214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
